C0004057||Aspirin
C0018270||Growth
C1335212||PI3K
C0678941||Mutant
C0678222||Breast Cancer
C2350345||AMP-activated protein kinase
C2975458||mTORC1
C0029016||oncogenic
C0026882||mutations
C1335212||PIK3CA
C3839127||gene encoding
C0600499||catalytic subunit
C0044602||PI3K
C0044602||PI3K
C0014432||inhibitors
C1333602||clinical benefit
C0678222||breast cancer
C0002783||epidemiologic studies
C0004057||aspirin
C0006826||cancers
C0044602||oncogenic PIK3CA
C0678941||mutant
C0044602||PIK3CA
C0017262||expressing
C1512505||breast cancer cells
C0004057||aspirin
C0007595||growth
C0007613||suppression
C1883559||wild-type
C0004057||Aspirin
C0007620||viability
C1515979||anchorage-independent growth
C0678941||mutant
C0044602||PIK3CA
C1512505||breast cancer cells
C1299583||independently
C0387583||COX-2
C0079904||NF-ÎºB
C0004057||aspirin
C2350345||AMP-activated protein kinase
C2350345||AMP-activated protein kinase
C2975459||mTORC1
C1519312||inhibition
C0004391||autophagy
C0029016||oncogenic
C0044602||PIK3CA
C0025929||mouse
C1458155||mammary tumors
C0004057||aspirin
C0087111||therapy
C0004057||aspirin
C0044602||PI3K
C0220825||evaluation
C0004057||aspirin
C0044602||PI3K
C1254351||inhibitors
C0087111||therapy
C0678222||breast cancer